Despite significant advances in CAR-T therapy, functional persistence remains limited by rapid T-cell exhaustion within the immunosuppressive tumor microenvironment and poor metabolic adaptation in "cold" solid tumors. Creative Biolabs' Metabolic Pre-conditioning platform addresses these hurdles by engineering support exosomes that deliver pro-survival signals directly to CAR-T cells. Through advanced Phospholipoproteomic Complex (PLP) conditioning and targeted metabolic reprogramming, we neutralize key inhibitory axes to sustain CAR-T bioenergetics and effector function. This service provides clients with exosome formulations that enhance CAR-T resilience, prolong in vivo persistence, and maintain potent antitumor activity under metabolically challenging conditions.
Pro-survival CAR-T support exosomes are engineered nano-sized vesicles derived from therapeutic T cells, designed to facilitate intercellular communication and deliver a protective bioactive cargo, including proteins, signaling lipids, and nucleic acids, to CAR-T cells in order to enhance their persistence, resistance to apoptosis, and overall metabolic fitness within the hostile tumor microenvironment. Metabolic Pre-conditioning for these pro-survival exosomes involves the strategic manipulation of parental CAR-T cell culture conditions prior to exosome harvest, thereby augmenting the vesicles' capacity to program recipient cells with superior metabolic robustness, fuel flexibility, and resistance to exhaustion upon adoptive transfer.
Fig.1 Exosomal metabolic priming for enhanced CAR-T cell viability.
Creative Biolabs offers a specialized platform for engineering "supportive" exosomes that function as metabolic shields for CAR-T cells. Through the pre-conditioning of producer cells, specifically semi-immortalized dendritic cells, using a proprietary PLP, the resulting exosomes are primed to actively remodel the immunosuppressive tumor microenvironment. These engineered vesicles deliver critical pro-survival signals and metabolic intermediates, thereby countering the induction of CD8+ T cell exhaustion typically triggered by tumor-derived metabolites such as hypoxanthine and lactate.
We provide a comprehensive suite of cutting-edge metabolic engineering services designed to enhance CAR-T cell therapy. Our platform focuses on two synergistic pillars: optimizing the CAR-T cells themselves and engineering their pro-survival support exosomes. Below is a summary of our specific service offerings.
Final Deliverables:
Q1: How do these exosomes specifically protect CAR-T cells from hypoxanthine?
A1: These specialized vesicles mediate protection by delivering a precisely calibrated payload of purine intermediate flux modulators. By replenishing rate-limiting metabolites that circumvent the enzymatic blockade imposed by tumor-derived hypoxanthine within the inosine salvage pathway, the exosomes sustain robust nucleotide biosynthesis. This metabolic recalibration ensures that CAR-T cells retain their proliferative capacity and functional integrity despite the suppressive purine-rich conditions prevalent in the tumor microenvironment.
Q2: Can these exosomes be used with any CAR-T construct?
A2: Absolutely. Our metabolic support platform is fundamentally construct-agnostic, engineered to address universal metabolic vulnerabilities rather than receptor-specific interactions. By targeting the metabolic "soil" rather than the CAR "seed," these pro-survival exosomes provide a versatile adjuvant that can be seamlessly integrated with any existing or future T-cell therapy design to enhance functional persistence and resistance to exhaustion.
Creative Biolabs positions itself at the vanguard of exosome engineering, pioneering a strategy that transcends conventional vesicle isolation. Our proprietary approach actively recalibrates the exosomal "metabolic blueprint" to precisely counteract distinct mechanisms of tumor immune evasion. Through an optimized PLP-conditioning protocol, we have achieved refined control over exosomal cargo packaging, tactically enriching vesicles with pro-inflammatory mediators while selectively suppressing the incorporation of immunosuppressive regulatory elements.
"Integrating Creative Biolabs' metabolic pre-conditioning into our pipeline has markedly enhanced CAR-T viability under metabolically hostile, hypoxanthine-rich conditions. Moreover, the lyophilized formulation dramatically streamlined our experimental workflow." Dr. Alen*** S.
"Treatment with these support exosomes resulted in potent downregulation of immunosuppressive cytokines IL-10 and TGF-β within the tumor niche, enabling our effector cells to sustain potent cytotoxic activity against aggressive, therapy-resistant melanoma models." Prof. Marc*** J.
"In direct comparison with conventional liquid nitrogen preservation, their lyophilized exosomes retained 92% functional integrity after six months of storage at 4°C, a transformative advantage that significantly simplifies the logistical and operational workflows of our multi-center trials." Dr. Kath*** L.
Unlock superior CAR-T efficacy with our Metabolic Pre-conditioning for Pro-survival CAR-T Support Exosomes. By leveraging stabilized, PLP-powered exosomal technology, we empower your therapies to overcome metabolic barriers of the TME for enhanced persistence. Inquire today to integrate this cutting-edge platform into your pipeline.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION